BlueCrest Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

BlueCrest Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-14,460	Closed	-$507K	–	982
2019 Q1	$507K	Buy	+14,460	New	+$538K	0.02%	481
2016 Q1	–	Sell	-13,925	Closed	-$187K	–	1085
2015 Q4	$187K	Buy	+13,925	New	+$215K	0.01%	872

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

NPIC

Neumeier Poma Investment Counsel Carmel, California $1.21B AUM 70.48% 1-Year Est. Return

BlueCrest Capital Management's SUPN Position: Q2 2019 in Review

BlueCrest Capital Management sold out of Supernus Pharmaceuticals (SUPN) in Q2 2019, closing a stake of 14,460 shares — an estimated $507K sold.

BlueCrest Capital Management first reported a position in SUPN in Q4 2015 and held it in 2 quarters. The position peaked at $507K in Q1 2019. 272 funds tracked by Wall St. Rank hold SUPN as of Q2 2019.

BlueCrest Capital Management reported no remaining Supernus Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
BlueCrest Capital Management sold 14,460 Supernus Pharmaceuticals shares in Q2 2019, an estimated $507K.
BlueCrest Capital Management first reported a position in Supernus Pharmaceuticals in Q4 2015 and held it in 2 quarters.
BlueCrest Capital Management's Supernus Pharmaceuticals position peaked at $507K in Q1 2019.
272 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2019.

Based on BlueCrest Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.